STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
BörsenkürzelSTAA
Name des UnternehmensSTAAR Surgical Co
IPO-datumFeb 24, 1992
CEOFarrell (Stephen C)
Anzahl der mitarbeiter1157
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 24
Addresse1911 Walker Ave
StadtMONROVIA
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl91016
Telefon16263037902
Websitehttps://www.staar.com/
BörsenkürzelSTAA
IPO-datumFeb 24, 1992
CEOFarrell (Stephen C)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten